Cyclosporine Market Outlook Highlights The Next Major Growth Opportunities
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Cyclosporine Market Size Outlook: How Fast Will Revenue Grow Through 2030?
The market for cyclosporine has seen significant expansion in recent times. Projected figures indicate an increase from $2.98 billion in 2025 to $3.37 billion in 2026, reflecting a compound annual growth rate (CAGR) of 13.0%. This upward trend observed historically is linked to a rise in organ transplant operations, proven effectiveness in suppressing immune responses, a growing incidence of autoimmune disorders, earlier regulatory clearances, and broader application of immunotherapy within hospital settings.
The cyclosporine market is projected to experience significant growth in the coming years, reaching a size of $5.46 billion by 2030, with a compound annual growth rate (CAGR) of 12.8%. This expansion during the forecast period is driven by factors such as the rising prevalence of chronic autoimmune conditions, an increasing burden of ophthalmic diseases, higher transplant survival rates, greater availability of generic versions, and the growing use of outpatient immunosuppressive therapies. Key trends shaping this period include the broader application of cyclosporine in managing autoimmune diseases, heightened uptake of ophthalmic formulations, a growing need for long-term immunosuppressive treatments, expanded use in organ transplant maintenance regimens, and a surge in generic cyclosporine product offerings.
Download A Free Sample Report For Comprehensive Market Insights:
Cyclosporine Market Development Factors: Which Trends Are Supporting Demand?
The anticipated expansion of the cyclosporine market is being driven by a rising incidence of autoimmune disorders. These conditions occur when the immune system erroneously attacks the body’s own cells, triggering inflammation, tissue deterioration, and persistent illness. This increase in autoimmune diseases can be linked to genetic susceptibility; with improvements in genetic screening, more individuals are being identified as having hereditary predispositions, rendering them more vulnerable to such illnesses. Cyclosporine proves beneficial in managing autoimmune diseases by inhibiting T-cell activation, thus dampening inappropriate immune responses aimed at healthy tissues, which is relevant to cases of rheumatoid arthritis, psoriasis, and lupus. As an example, a comprehensive review published in October 2024 in Signal Transduction and Targeted Therapy—a journal from Nature, a UK-based peer-reviewed scientific publisher—indicates that about 8.4 million individuals worldwide are affected by rheumatoid arthritis, with the overall incidence rising by 2–3% each year; according to projections using the Markov model, the number of affected people is expected to reach approximately 13.5–17.4 million by 2040. Consequently, the growing frequency of autoimmune diseases is fueling the growth of the cyclosporine market.
Cyclosporine Market Segment Analysis: What Are The Major Market Categories?
The cyclosporine market covered in this report is segmented –
1) By Indication: Transplant Rejection Prophylaxis, Rheumatoid Arthritis, Psoriasis, Autoimmune Myasthenia Gravis, Dry Eye, Other Indications
2) By Dosage Form: Capsule, Eye Drops, Liquid Solutions, Creams And Ointments
3) By Route Of Administration: Oral, Topical, Parenteral
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End-Users: Hospitals, Homecare, Speciality Centres, Other End-Users
Subsegments:
1) By Transplant Rejection Prophylaxis: Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant, Other Transplants
2) By Rheumatoid Arthritis: Moderate Rheumatoid Arthritis, Severe Rheumatoid Arthritis
3) By Psoriasis: Plaque Psoriasis, Erythrodermic Psoriasis, Guttate Psoriasis, Pustular Psoriasis
4) By Autoimmune Myasthenia Gravis: Generalized Myasthenia Gravis, Ocular Myasthenia Gravis
5) By Dry Eye: Chronic Dry Eye, Severe Dry Eye
6) By Other Indications: Atopic Dermatitis, Uveitis, Nephrotic Syndrome, Inflammatory Bowel Disease (IBD)
Cyclosporine Market Transformation Trends: Which Innovations Are Driving Change?
Leading players in the cyclosporine market are actively pursuing regulatory approvals as a strategic move to broaden their product offerings and strengthen their competitive footprint. These official endorsements confirm the drug’s safety and effectiveness, clearing the path for market entry and fostering greater trust among both healthcare providers and patients. A clear example occurred in June 2023, when Novaliq GmbH, a biopharmaceutical firm headquartered in Germany, secured U.S. FDA approval for VEVYE (cyclosporine ophthalmic solution) 0.1%. This represents the first and only cyclosporine-based treatment specifically designed for dry eye disease (DED), delivering noticeable results in as little as four weeks. VEVYE leverages a groundbreaking water-free technology called EyeSol, which boosts cyclosporine’s bioavailability and extends its retention time on the eye’s surface, all while excluding preservatives, oils, or surfactants. Acting as a calcineurin inhibitor, this solution effectively curbs the inflammation typically associated with DED.
Cyclosporine Market Leading Companies Driving Competitive Growth
Major companies operating in the cyclosporine market are Novartis AG, Viatris Inc., Teva Pharmaceutical Industries Ltd, Sandoz International GmbH, Sun Pharmaceutical Industries Ltd, Apotex Inc., Cipla Ltd, Dr. Reddy’s Laboratories Ltd, Lupin Limited, Glenmark Pharmaceuticals Ltd, Taj Pharmaceuticals Limited, Panacea Biotec Ltd, Novaliq GmbH, Simson Pharma Limited, Strides Pharma Science Ltd, AdvaCare Pharma, JoinHub Pharma, Grevis Pharmaceuticals Pvt Ltd, GMT Pharma International, Logos Pharma.
Access The Complete Cyclosporine Market Report:
Cyclosporine Market Geographic Distribution And Regional Opportunities
Asia-Pacific was the largest region in the cyclosporine market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the cyclosporine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
